ArticleFrontiers in oncology2025
External validation of the Oncotype DX breast cancer recurrence score nomogram and development and validation of a novel machine learning-based model to predict postoperative overall survival and guide adjuvant chemotherapy in ER positive, Her-2 negative breast cancer patients: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to externally validate the performance of the Oncotype DX (ODX) breast cancer (BC) recurrence score nomogram in predicting adjuvant chemotherapy (ACT) for BC after surgery and subsequently develop a machine learning-based model to predict postoperative overall survival (OS) and guide ACT, demonstrating superior comprehensive performance. Methods: This analysis leveraged data from the SEER database spanning 2010-2020, alongside a BC cohort from the Beijing Hospital (BJH). Machine learning methods were applied for predictor selection by wrapper methods and the development of the predictive model. The optimal model was determined using the concordance index (C-index), time-dependent calibration curves, time dependent receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). The benefit analysis of ACT was primarily conducted using Kaplan-Meier survival analysis. Results: The ODX nomogram performed poorly in predicting ACT benefit in both the SEER cohort and the BJH cohort. Subsequently, we employed ten machine learning methods to develop ten prognostic models. The Accelerated oblique random survival forest model (AORSFM), exhibiting the highest prediction performance, was selected. The C-index for AORSFM is 0.799 (95% CI 0.779-0.823) in the SEER cohort and 0.793 (95% CI 0.687-0.934) in the BJH cohort. Furthermore, time-dependent calibration curves, time-dependent ROC analysis, and DCA indicate that the AORSFM demonstrates good calibration, predictive accuracy, and clinical net benefit. A publicly accessible web tool was developed for the AORSFM. Notably, the new staging system based on AORSFM can provide guidance for postoperative ACT in such patients. Conclusions: The AORSF has the potential to identify postoperative OS and guide ACT in patients with BC. This can assist clinicians in assessing the severity of the disease, facilitating patient follow-up, and aiding in the formulation of adjuvant treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.